Medicure (TSXV:MPH) Research & Development: C$3.46 Mil (TTM As of Mar. 2026)


TSXV:MPH Medicure Inc TSXV:MPH
64 GF Score
Price C$1.28
GF Value C$1.55
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Medicure Research & Development?

Medicure TSXV:MPH 64 Research & Development is C$3.46 Mil as of Mar. 2026. GuruFocus rates TSXV:MPH with a GF Score™ of 64/100 and a GF Value™ of C$1.55 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medicure's Research & Development for the three months ended in Mar. 2026 was C$0.86 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was C$3.46 Mil.

Medicure  (TSXV:MPH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medicure Research & Development Related Terms

Medicure Research & Development Historical Data

* Premium members only.

The historical data trend for Medicure's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicure Research & Development Chart

Medicure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.80 2.75 2.41 3.08 3.18

Medicure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.74 0.72 1.15 0.86
TSXV:MPH
64GF Score
Medicure Inc TSXV:MPH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicure Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$3.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of C$3.46 Mil mean?
Medicure (TSXV:MPH) has a Research & Development of C$3.46 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Medicure and its competitors.
Is Medicure's Research & Development too high?
Medicure's current Research & Development is C$3.46 Mil. Overall, Medicure has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medicure's Research & Development compare to ZTS?
Medicure's Research & Development of C$3.46 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medicure and its competitors. Medicure's current Research & Development is C$3.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicure stock overvalued right now?
Based on GuruFocus' analysis, Medicure (TSXV:MPH) is currently considered Modestly Undervalued. The stock's GF Value™ is C$1.55, compared to a current price of C$1.28 — trading 17.4% below its estimated fair value. The current Research & Development is C$3.46 Mil. Medicure's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medicure (TSXV:MPH), the current Research & Development is C$3.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicure (TSXV:MPH) Overvalued in 2026?

Based on GuruFocus' analysis, Medicure stock appears to be undervalued. The current stock price of C$1.28 is trading 17.4% below its estimated GF Value™ of C$1.55. GuruFocus considers Medicure to be Modestly Undervalued.

Key valuation signals for TSXV:MPH:

  • Research & Development: C$3.46 Mil
  • GF Value™: C$1.55 vs. price of C$1.28 (17.4% below fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the TSXV:MPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicure Business Description

Other Exchanges MCUJF:USA
Address 1250 Waverley Street, No. 2, Winnipeg, MB, CAN, R3T 6C6
Medicure Inc is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and increasing its e-commerce and mail order pharmaceutical business. The Company operates under two segments: the marketing and distribution of commercial products and the operation of a retail and mail order pharmacy. It generates the majority of its revenue from the Retail and Mail Order Pharmacy segment.
64GF Score

Get the complete analysis for TSXV:MPH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$1.28
Price
C$1.55
GF Value